Leerink Partners assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $44.00 price target on the stock.
Several other research firms have also recently issued reports on ORKA. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a report on Monday. They issued an outperform rating and a $41.00 price objective for the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Friday, September 13th. They set a buy rating and a $40.00 price target for the company. Wedbush assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They issued an outperform rating and a $40.00 target price on the stock. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research note on Monday. They set a buy rating for the company. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Buy and an average target price of $41.25.
Check Out Our Latest Analysis on ORKA
Oruka Therapeutics Stock Down 2.2 %
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More
- Five stocks we like better than Oruka Therapeutics
- Comparing and Trading High PE Ratio Stocks
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- There Are Different Types of Stock To Invest In
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Investing in Travel Stocks Benefits
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.